TPMT抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P02868(TPMT Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The thiopurine S-methyltransferase (TPMT) antibody is associated with the detection or study of TPMT, an enzyme critical in metabolizing thiopurine drugs like azathioprine, 6-mercaptopurine, and 6-thioguanine. These drugs are used to treat autoimmune disorders, inflammatory bowel disease, and leukemia. TPMT catalyzes the methylation of thiopurines, influencing their efficacy and toxicity. Genetic polymorphisms in the TPMT gene can lead to variable enzyme activity: individuals with low or absent TPMT activity are at high risk of severe myelosuppression due to drug accumulation.

Anti-TPMT antibodies are not typically part of routine clinical testing but may be researched in autoimmune contexts. In rare cases, autoantibodies against TPMT have been reported, potentially interfering with enzyme function or diagnostic assays. For example, in autoimmune hepatitis or lupus, such antibodies might contribute to altered drug metabolism or misinterpretation of TPMT activity levels. However, standard practice focuses on TPMT genotyping or phenotyping (enzyme activity measurement) to guide dosing, rather than antibody detection. Research on TPMT antibodies remains niche, exploring their role in drug resistance, assay interference, or autoimmune mechanisms. Clinically, understanding TPMT variability remains pivotal to personalize thiopurine therapy and minimize adverse effects.